Search results
4 kwi 2012 · Malignant ascites indicates the presence of malignant cells in the peritoneal cavity and is a grave prognostic sign. While survival in this patient population is poor, averaging about 20 wk from time of diagnosis, quality of life can be improved through palliative procedures.
12 wrz 2023 · Paramalignant ascites is the formation of ascites in patients with cancer without the cytologic proof of tumor cells. This condition may be caused by cancer-related comorbidities such as liver cirrhosis, portal vein obstruction, heart failure, pancreatitis or infections.
20 lis 2021 · This article summarizes the section of treatment of malignant ascites in a clinical practice guideline for peritoneal dissemination (PD) caused by various abdominal malignancies. It reviews the evidence and recommendations for four clinical questions related to drainage, shunting and reinfusion therapy for PD patients.
27 lut 2024 · Learn about the causes, mechanisms, and management of ascites related to malignant disease. This article covers various tumor types, peritoneal carcinomatosis, and chylous ascites.
31 mar 2012 · Malignant ascites (MA) is a pathological condition due to a variety of primary abdominal and extra-abdominal neoplasms. It is a primary cause of morbidity and presents many difficulties and treatment challenges.
Malignant ascites is a manifestation of end stage events in a variety of cancers and is associated with significant morbidity. It accounts for about 10% of all cases of ascites and usually caused by ovarian, endometrial, breast, oesophageal, gastric, colorectal, lung, pancreatic, hepatobiliary and primary peritoneal carcinomas [ 1–3 ].
The guidelines summarize the general aspect of the treatment of malignant ascites and statements with recommendation strengths, evidence levels, agreement rates and future perspective for four raised clinical questions.
